Gilead Sciences
Gilead Sharing Keytruda, Trodelvy Triple-Negative Breast Cancer Data With Regulators
In a Phase III trial, the Keytruda-Trodelvy combo improved progression-free survival in patients with PD-L1-positive tumors compared to Keytruda-chemo.
Ideaya Begins Trial Expansion of IDE397, Trodelvy in MTAP-Deletion Urothelial Cancer
The firm is evaluating its MAT2A inhibitor IDE397 with Trodelvy in urothelial and non-small cell lung cancers with MTAP deletions.
In Brief This Week: OncoInv, Eisai, Biogen, Roche, Gilead, CSL Behring, Paige
News items for the week of March 31, 2025.
Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.
JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
Dec 30, 2024